Currently out of the existing stock ratings of Yanan Zhu, 66 are a BUY (80.49%), 16 are a HOLD (19.51%).

Yanan Zhu

Work Performance Price Targets & Ratings Chart

Analyst Yanan Zhu, currently employed at WELLS FARGO, carries an average stock price target met ratio of 44.76% that have a potential upside of 55% achieved within 78 days.

Yanan Zhu’s has documented 163 price targets and ratings displayed on 23 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on IONS, Ionis Pharmaceuticals at 22-Aug-2025.

Wall Street Analyst Yanan Zhu

Analyst best performing recommendations are on AGLE (AEGLEA BIO THERAPEUTICS).
The best stock recommendation documented was for AGLE (AEGLEA BIO THERAPEUTICS) at 10/28/2022. The price target of $37.5 was fulfilled within 13 days with a profit of $14.5 (63.04%) receiving and performance score of 48.49.

Average potential price target upside

of $84.46 (21.84%) on ARGX (ARGENX NV ADR).
of $32.66 (24.14%) on BLUE (BLUEBIRD BIO).
of $14.35 (69.56%) on MNTA (MOMENTA PHARMACEUTICALS).

ARGX argenx NV ADR EDIT Editas Medicine RAPT RAPT Therapeutics AVRO AVROBIO BLUE Bluebird bio SGMO Sangamo Therapeutics AGLE Aeglea Bio Therapeutics AGTC Applied Genetic TSHA Taysha Gene Therapies BEAM Beam Therapeutics NTLA Intellia Therapeutics AFMD Affimed NV AUTL Autolus Therapeutics Ltd FATE Fate Therapeutics IOVA Iovance Biotherapeutics RNA Avidity Biosciences GRCL Gracell Biotechnologies TCRT Alaunos Therapeutics IONS Ionis Pharmaceuticals SYRE Spyre Therapeutics ARCT Arcturus Therapeutics Holdings CCXI ChemoCentryx MNTA Momenta Pharmaceuticals

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Matthew Harrison (MORGAN STANLEY)